MAY 21, 2019 11:25 AM PDT

Benralizumab not effective reducing exacerbations of COPD

WRITTEN BY: Nouran Amin

According to the American Lung Association, chronic obstructive pulmonary disease (COPD) is the third leading cause of death in this country. More than often, patients go through potentially life-threatening exacerbations, including days-long flare-ups of symptoms, shortness of breath, swelling and mucus.

Now, a recent study published in the New England Journal of Medicine, shows that a drug used as a therapeutic for asthma, has failed to reduce symptoms of COPD. The drug is called benralizumab and is interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that is FDA approved to treat severe eosinophilic asthma—the presence of high amounts of eosinophils (a particular type of immune cell) exacerbates the symptoms of COPD.

"COPD is a life-altering condition that causes serious long-term disability for patients," said Dr. Criner, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University, Director of the Temple Lung Center and corresponding author on the study. "Discovering treatments that prevent and/or limit exacerbations is a priority for clinicians and researchers as we seek to improve the quality of life for patients. Unfortunately benralizumab did not accomplish that objective in these studies, but the findings will inform current and future avenues of exploration for new treatments."

However, an earlier phase II trial found that benralizumab had a non-statistically significant reduction in COPD exacerbation rate for patients with eosinophilic inflammation in their airways.

"The findings in these two trials suggest that eosinophil depletion may not completely ameliorate exacerbation outcomes for patients with COPD," added Dr. Criner. "However, as one of the nation's premier lung-disease research centers, the Temple Lung Center continues to investigate alternative treatment options and offer patients access to leading-edge clinical trials."

Source: Temple Health

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAR 04, 2021
Drug Discovery & Development
How Placebo Drugs for Pain Work in the Brain
MAR 04, 2021
How Placebo Drugs for Pain Work in the Brain
Researchers from Dartmouth College have found that pain relief drugs that work via the placebo effect reduce pain-relate ...
MAR 18, 2021
Drug Discovery & Development
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
MAR 18, 2021
New Cancer Immunotherapy Targets Genetic Alteration in All Cancers
Researchers have developed a prototype for a new kind of cancer immunotherapy. The therapy uses engineered T-cells to ta ...
MAR 05, 2021
Drug Discovery & Development
Personalized Treatment for Sickle Cell Disease
MAR 05, 2021
Personalized Treatment for Sickle Cell Disease
Globally, the most prevalent inherited blood disease is sickle cell which affects 70,000 to 100,000 Americans. Despite s ...
MAR 30, 2021
Microbiology
A Marburg Virus Treatment Approach is Identified
MAR 30, 2021
A Marburg Virus Treatment Approach is Identified
Marburg virus causes severe hemorrhagic fever; its fatality ratio can be as high as 88 percent. Researchers may have now ...
APR 05, 2021
Neuroscience
Could a Keto Diet Treat Alzheimer's Disease?
APR 05, 2021
Could a Keto Diet Treat Alzheimer's Disease?
  Researchers from Brigham Young University have found evidence that eating a ketogenic diet- which is a diet that ...
MAY 25, 2021
Cell & Molecular Biology
A simplified high-throughput protein expression system
MAY 25, 2021
A simplified high-throughput protein expression system
Protein synthesis, protein engineering, and synthetic biology researchers can research their protein of interest using e ...
Loading Comments...